SELUTION DeNovo Trial Results
The SELUTION DeNovo randomized clinical trial,! presented at TCT 2025 in San Francisco, USA, demonstrates non-inferiority of the SELUTION SLR sirolimus-eluting balloon to standard-of-care for in-stent restenosis.
A percutaneous coronary intervention (PCI) strategy using the SELUTION SLR sirolimus-eluting balloon with provisional stenting was found to be non-inferior to the systematic use of drug-eluting stents (DES) for the treatment of de novo coronary lesions at one year.
The trial was designed to test whether a stent-minimizing approach could achieve outcomes comparable to standard DES implantation.
Author's summary: SELUTION DeNovo trial shows non-inferiority of drug-eluting balloon.
- The trial involved 62 participating sites across 12 countries in Europe and Asia.
- Drug-eluting stents are associated with a persistent annual 2–4% rate of very-late adverse cardiovascular events.
More News
- Pivoting from Exploration to Production: Mining's Moment
- Brookfield/Cameco-owned Westinghouse secures US nuclear construction deal
- Banging bumper fun from 2000AD!
- We need more faith spaces that affirm the LGBTQ communities – Baptist News Global
- Adobe Announces AI Assistants, Firefly Models, More
- The Hidden Health Risks of Neglected Carpets and Upholstery | NorthPennNow
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub
- Elon Musk’s Unveils Grokipedia - IT News Africa | Business Technology, Telecoms and Startup News
- Pivoting from Exploration to Production: Mining's Moment
- 'Chainsaw Man - The Movie: Reze Arc' Review — A Beautifully Chaotic Anime